{
    "2020-06-01": [
        [
            {
                "time": "",
                "original_text": "235亿天价分手费背后：康泰生物千亿估值隐忧",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "分手费",
                        "千亿估值",
                        "隐忧"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药行业周报：关注后疫情时代公共卫生体系的建设",
                "features": {
                    "keywords": [
                        "医药行业",
                        "后疫情时代",
                        "公共卫生体系",
                        "建设"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}